Health Sciences

National Trial Shows Equal Efficacy of Two Medications Used to Treat Age-Related Macular Degeneration

Age-related macular degeneration (AMD), a disease that damages the retina and can destroy central vision, affects approximately 1.6 million Americans. For the past five years, there has been active debate over treatment options for AMD patients because ophthalmologists have not had accurate data regarding the true efficacy of the most commonly used medication.

Jessica Mikulski

Penn Study: Preventing Chronic Diseases in People Living With HIV/AIDS

A new study in the Archives of Internal Medicine shows that interventions to promote healthy behaviors, including eating more fruits and vegetables, increasing physical activity, and participating in cancer screenings appear beneficial for African-American couples who are at high risk for chronic diseases, especially if one of the individuals is living with HIV (human immunodeficiency virus).

Joe Diorio



In the News


Philadelphia Inquirer

She’s an expert on OCD at Penn. It still took a while to recognize the disorder in her five-year-old son

Emily Becker-Haimes of the Perelman School of Medicine shares how she recognized OCD in her son’s behavioral habits.

FULL STORY →



The New York Times

You’ve lost weight taking new obesity drugs. What happens if you stop?

Mitchell A. Lazar of the Perelman School of Medicine says that there’s no “magic bullet” for lowering the dosage of weight-loss medication while keeping the weight off.

FULL STORY →



HealthDay

Dementia may not be as common among Parkinson’s patients as thought

A study by Daniel Weintraub of the Perelman School of Medicine suggests that dementia is not inevitable with Parkinson’s and is actually less common than presumed.

FULL STORY →



Forbes

Carl June: 2024 will be seen as a breakthrough year for brain cancer

Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.

FULL STORY →



Nature

Second brain implant by Elon Musk’s Neuralink: Will it fare better than the first?

Anna Wexler of the Perelman School of Medicine and Leonard Davis Institute says that Elon Musk’s predictions for Neuralink’s health care capabilities risk misleading potential study volunteers.

FULL STORY →